Myloxifin (Naloxone Hydrochloride, Oxycodone Hydrochloride)

Naloxone Hydrochloride and Oxycodone Hydrochloride, the active ingredients in Myloxifin, form a combination opioid analgesic and opioid antagonist presented as an oral tablet for the management of moderate to severe pain in adult patients requiring opioid therapy.

GNH USA supplies Myloxifin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across global markets and providing reliable logistics for timely delivery.

Myloxifin, a combination of an opioid agonist and antagonist, is indicated for pain management within the opioid pathway.

Moderate to severe acute pain: provides effective analgesia while reducing the risk of opioid‑induced constipation and respiratory depression. Chronic cancer‑related pain: maintains pain control with lower abuse potential. Post‑operative pain: offers rapid onset analgesia with built‑in abuse deterrence.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Constipation: reduced bowel motility. - Dizziness: transient light‑headedness. - Headache: mild cranial discomfort.

Serious or Rare Side Effects: - Respiratory depression: severe reduction in breathing rate. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, pruritus, or anaphylaxis. - Opioid withdrawal syndrome: symptoms if naloxone effect predominates. - Seizures: rare neurologic events.

Myloxifin should be prescribed with careful clinical assessment and monitoring.

Assess pain level: ensure opioid therapy is appropriate before prescribing. Monitor for signs of opioid dependence: watch for cravings or misuse behaviors. Evaluate renal and hepatic function: adjust if impairment present. Avoid use in patients with known hypersensitivity to either component. Store at ambient temperature: keep in original container, protect from moisture and light.

Myloxifin may interact with several medications; clinicians should review patient regimens.

Major Interactions (Avoid): - Concomitant use with other opioids: risk of additive respiratory depression. - MAO inhibitors: may precipitate severe hypertension or serotonin syndrome. - Benzodiazepines: increased sedation and respiratory risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase oxycodone levels. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Anticholinergic agents: may exacerbate constipation.